Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the wall. Still, these are the moments when shareholders should quit treating a cash offer like a gift basket and start reading the fine print.
Each Deal Has a Clean Headline Price
The announced consideration is straightforward enough. Surgery Partners, NASDAQ:SGRY, is set to be sold to HealthSpan Partners for $23.50 in cash per share. Braze, NASDAQ:BRZE, is proposed to go to Salesforce for $47.50 in cash per share. CCC Intelligent Solutions, NASDAQ:CCC, is proposed to be acquired by affiliates of GTCR and Elliott Investment Management for $7.75 in cash per share.
Cash deals carry a particular psychological trick. They end uncertainty quickly, put a definite number in front of people, and make it easy for boards to say they have delivered certainty. Maybe they have. But certainty is not the same thing as full value. A shareholder only gets one chance to sell once a company is taken private or folded into a larger buyer. There is no participation in the next strong quarter, no upside from a better bidder appearing after the vote, and no do-over if the market later decides the business was worth materially more.
- Surgery Partners holders are being offered $23.50 per share in cash.
- Braze holders are being offered $47.50 per share in cash.
- CCC Intelligent Solutions holders are being offered $7.75 per share in cash.
The Process Matters as Much as the Number
Halper Sadeh says it is examining potential federal securities-law violations and possible breaches of fiduciary duties in connection with the transactions. The firm specifically flags two familiar pressure points: substantial financial benefits that insiders may receive beyond what ordinary shareholders receive, and deal terms that may limit superior competing offers.
Neither issue proves a deal is crooked. It does mean the proxy materials, fairness analysis, merger agreement and board process deserve real attention. Management retention packages, equity-treatment arrangements, rollover interests, transaction bonuses, accelerated awards and severance protections can all affect incentives. A director or executive may sincerely believe a deal is good while also having a personal reason to prefer one buyer, one timetable, or one outcome. That is precisely why disclosure is not some paperwork nuisance. It is the evidence trail shareholders use to judge whether the people running the auction were truly pulling for them.
Locked Doors Deserve a Hard Look
The language about restrictions on superior offers is especially worth watching. Merger agreements often contain no-shop clauses, matching rights, termination fees, information limits, or other provisions designed to give a buyer confidence that it will not be used as a stalking horse. Some degree of protection is ordinary commerce. Buyers do not spend months negotiating just to invite an instant bidding war on their own dime.
Yet a board cannot hide behind “ordinary” when the practical effect is to chill a credible better offer. The relevant question is not whether a restriction has a respectable name in deal-world jargon. The question is whether the package of restrictions, timing, incentives and disclosures left shareholders with a meaningful chance at the best available value. That is the meat of it. Everything else is garnish.
What Investors Should Separate From the Noise
Law-firm investigations following merger announcements are common, and a press release alone tells investors very little about whether a claim will succeed. Halper Sadeh states that it may seek increased consideration, added disclosures and information, or other relief for shareholders. It also says it would handle matters on a contingent-fee basis, meaning clients would not be responsible for out-of-pocket legal fees or expenses. Those are the firm’s stated positions, not promises of a particular result.
For holders, the sensible move is dull but necessary: compare the cash price with the company’s recent trading range, understand what the board says about its process, and scrutinize disclosures concerning management incentives and deal protections when they become available. Do not assume every investigation means disaster. Do not assume a premium automatically settles the value question either. These three transactions may be fair, or they may warrant sharper negotiation and fuller disclosure. Until the record is out in the open, certainty is the one thing shareholders should not pretend to have.